Fixx lawsuit alert: levi & korsinsky notifies homology medicines, inc

Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) of a class action securities lawsuit.


The Fixx lawsuit seeks to recover losses on behalf of Homology investors who were adversely affected by alleged securities fraud between June 10, 2019 and February 18, 2022. Follow the link below to get more information and be contacted by a member of our team:


The Fixx filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.


If you suffered a loss in Homology during the relevant time frame, you have until May 24, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.


If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.


Over the past 20 years, the team at Fixx lawsuit Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.

Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients.

For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

This article was shared with Prittle Prattle News as a Press Release.

Must Read-  EduCrack aligns with

Follow Us: Facebook Instagram | Twitter YouTube | LinkedIn Pinterest Tumblr

Related Posts

1 of 1,089

Leave A Reply

Your email address will not be published. Required fields are marked *